M&T Bank
NVCR icon

M&T Bank’s NovoCure NVCR Stock Holding History

M&T Bank’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,634
Closed -$189K – 1602
2025
Q1 		$189K Sell
10,634
-1,750
-14% -$39.7K ﹤0.01% 1426
2024
Q4 		$369K Sell
12,384
-457
-4% -$9.67K ﹤0.01% 1295
2024
Q3 		$201K Sell
12,841
-3,178
-20% -$57.6K ﹤0.01% 1523
2024
Q2 		$275K Buy
16,019
+913
+6% +$16.1K ﹤0.01% 1351
2024
Q1 		$236K Buy
+15,106
New +$222K ﹤0.01% 1431
2023
Q3 		– Sell
-4,979
Closed -$206K – 1648
2023
Q2 		$206K Buy
4,979
+22
+0.4% +$1.37K ﹤0.01% 1462
2023
Q1 		$298K Buy
4,957
+1,058
+27% +$84.5K ﹤0.01% 1305
2022
Q4 		$286K Sell
3,899
-876
-18% -$65.9K ﹤0.01% 1323
2022
Q3 		$362K Sell
4,775
-301
-6% -$23.5K ﹤0.01% 1208
2022
Q2 		$347K Sell
5,076
-193
-4% -$14.5K ﹤0.01% 1126
2022
Q1 		$435K Buy
5,269
+2,292
+77% +$169K ﹤0.01% 1052
2021
Q4 		$224K Buy
2,977
+211
+8% +$21.2K ﹤0.01% 1394
2021
Q3 		$322K Sell
2,766
-379
-12% -$57.3K ﹤0.01% 1199
2021
Q2 		$697K Buy
3,145
+238
+8% +$46.3K ﹤0.01% 881
2021
Q1 		$383K Sell
2,907
-3,117
-52% -$493K ﹤0.01% 1116
2020
Q4 		$1.04M Sell
6,024
-126
-2% -$17.2K ﹤0.01% 760
2020
Q3 		$685K Buy
6,150
+2,647
+76% +$212K ﹤0.01% 842
2020
Q2 		$208K Sell
3,503
-5
-0.1% -$329 ﹤0.01% 1364
2020
Q1 		$236K Buy
3,508
+163
+5% +$12.9K ﹤0.01% 1258
2019
Q4 		$282K Sell
3,345
-229
-6% -$18.5K ﹤0.01% 1116
2019
Q3 		$267K Sell
3,574
-639
-15% -$51.1K ﹤0.01% 1263
2019
Q2 		$266K Buy
4,213
+13
+0.3% +$659 ﹤0.01% 1289
2019
Q1 		$202K Buy
+4,200
New +$202K ﹤0.01% 1414

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

M&T Bank's NVCR Position: Q2 2025 in Review

M&T Bank sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 10,634 shares — an estimated $189K sold.

M&T Bank first reported a position in NVCR in Q1 2019 and held it in 23 quarters. The position peaked at $1.04M in Q4 2020. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • M&T Bank reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • M&T Bank sold 10,634 NovoCure shares in Q2 2025, an estimated $189K.
  • M&T Bank first reported a position in NovoCure in Q1 2019 and held it in 23 quarters.
  • M&T Bank's NovoCure position peaked at $1.04M in Q4 2020.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on M&T Bank's 13F filing for Q2 2025, filed 13 Aug 2025.